Almirall's uncertainty on 2020 earnings hits share price

24 February 2020
almirall-location-big-1

The Coronavirus hit markets on Monday morning, with the uncertainty around its impact doing damage to the share prices of many pharma and biotech companies.

But a company that had a particularly bad morning in the stock market was Almirall (ALM: MC), the Spanish dermatology specialist, which presented its full-year 2019 financial results and its outlook for 2020. The latter is likely to be responsible for the 3% reduction in the firm’s share price as trading entered its final third.

The annual revenue figure, of 908.4 million euros ($983 million) showed healthy growth of 12% compared to 2018, and earnings before interest, taxes, depreciation and amortization (EBITDA) jumped by 45% to 304.2 million euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical